Partnering opportunity

Preoperative marker for diagnosis and differentiation of renal carcinoma.


A German university has developed a marker for non-invasive diagnosis and differentiation of benign and malignant renal carcinoma. An unequivocal differentiation will improve the planning of the adequate treatment. The university offers a license agreement.

Partner sought

The university offers a license agreement Potential licensees come from the diagnostic industry. Especially those companies that offer immunohistochemical analyses and investigations in body fluids (by means of antibody detection) are addressed, specifically urine diagnostics. The cooperation would include the further development to a ready to use product. This involves the relevant studies. Meanwhile the prototype is under development (test strip and ELISA test).


Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytomas. The unequivocal differentiation is essential for planning the adequate operative procedure and the patient follow-up monitoring (which is not necessary for oncocytomas). To date, it is not possible to reliably differentiate between malignant subtypes and benign kidney tumors by means of the available antibody panel and imaging methods. A German university found a splice isoform of Vimentin, namely Vimentin3 (Vim3), as an indicator of benign oncocytomas. Renal cell carcinomas (RCCs) are negative for Vim3. They also discovered a truncated variant of the protein MAPK p38, namely Mxi-2, which indicates RCC, including all subtypes. Oncocytomas, however, is negative for Mxi-2. Both markers are detectable by means of monoclonal antibodies directed against Vim3 and Mxi-2 in body fluids, such as urine, as well as in tissue. Detection of both markers in urine makes it possible for the first time to provide urologists and oncologists with a non-invasive test for a pre-operative diagnosis so as to appropriately treat the patient and plan the follow-up. The marker is also usable for routine medical check-ups (for persons aged 55 and above). The university offers a license agreement to companies from the diagnostic industry. The partner should cooperate to further develop the prototype to a final product.

Advantages and innovations

The identified vimentim3 represents a novel approach to differentiate a benign oncocytoma from malignant carcinomas. Apart from the fact that this procedure will improve the diagnosis it will also optimize the treatment of the patients.

Development stage

Available for demonstration

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company